PlumBot: Bot: Creating new article from JSON

2026-03-13T13:06:41Z

Bot: Creating new article from JSON

New page

💊 '''Pharmacy and therapeutics committee''' is a clinical governance body within a [[Definition:Health insurance | health insurance]] plan or [[Definition:Managed care | managed care]] organization that evaluates and selects which medications will be included on the plan's [[Definition:Formulary | formulary]]. Composed of physicians, pharmacists, and other healthcare professionals, the committee applies evidence-based criteria — including clinical efficacy, safety profiles, and cost-effectiveness — to determine which drugs an insurer will cover and under what conditions. While hospitals and health systems also maintain such committees for internal use, in the insurance context the committee's decisions directly shape the benefit design and pharmaceutical cost structure of the plan.

⚙️ The committee typically meets on a regular cycle to review new drug approvals, assess therapeutic equivalents, and reconsider existing formulary placements based on emerging clinical data or shifting market pricing. When a new medication reaches the market, the committee weighs whether it offers meaningful clinical advantages over existing [[Definition:Generic drug | generic]] or [[Definition:Brand-name drug | brand-name]] alternatives already on the formulary, and it may assign the drug to a specific [[Definition:Formulary tier | tier]] that determines the [[Definition:Copayment | copayment]] or [[Definition:Coinsurance | coinsurance]] a member pays. In many managed care structures, the committee also collaborates with the plan's [[Definition:Pharmacy benefit management (PBM) | pharmacy benefit manager]] to negotiate [[Definition:Rebate | rebates]] and establish [[Definition:Prior authorization | prior authorization]] or [[Definition:Step therapy | step therapy]] requirements that control utilization.

🔍 The decisions made by a pharmacy and therapeutics committee ripple across the entire economics of a health plan. A well-managed formulary can significantly reduce [[Definition:Medical loss ratio (MLR) | medical loss ratio]] pressure by steering utilization toward cost-effective therapies without compromising clinical outcomes, while a poorly constructed one can drive member dissatisfaction and increase [[Definition:Appeals process | appeals]] volume. Regulatory frameworks in the United States, such as those enforced by the [[Definition:Centers for Medicare and Medicaid Services (CMS) | Centers for Medicare & Medicaid Services]] for [[Definition:Medicare Part D | Medicare Part D]] plans, impose specific requirements on committee composition and transparency. In other markets — particularly those with national health insurance systems in Europe and Asia — analogous bodies such as the UK's National Institute for Health and Care Excellence or Japan's Central Social Insurance Medical Council perform a similar gatekeeping function at the national level, though the structure and decision-making authority differ from the insurer-level committees typical in the U.S. managed care landscape.

'''Related concepts:'''
{{Div col|colwidth=20em}}
* [[Definition:Formulary]]
* [[Definition:Pharmacy benefit management (PBM)]]
* [[Definition:Prior authorization]]
* [[Definition:Managed care]]
* [[Definition:Medical loss ratio (MLR)]]
* [[Definition:Step therapy]]
{{Div col end}}

Definition:Pharmacy and therapeutics committee - Revision history

PlumBot: Bot: Creating new article from JSON